anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/US96/09607 Sec. 371 Date Feb. 11, 1998 Sec. 102(e) Date Feb. 11, 1998 PCT Filed Jun. 7, 1996 PCT Pub. No. WO96/40192 PCT Pub. Date Dec. 19, 1996A method for increasing bioavailabilty of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration 0.01 wt. % or less in an assay that measures reduced conversion of cyclosporine to hydroxylated products using an assay system containing 250  mu g rat liver microsomes, 1  mu M cyclosporine, and 1  mu M reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4.
We report the case of a man in his 50s with extravascular haemolysis, fluctuating indirect hyperbilirubinaemia, elevated transferrin saturation with hyperferritinaemia and normal liver enzymes. Spherocytes were detected in a blood smear and a mutation of unknown significance, c.1626+1G>A p.?, in intron 13 of the SLC4A1 gene, was identified by next-generation sequencing (NGS). The same mutation was found in his daughter, who presented with similar laboratory changes, confirming the diagnosis of hereditary spherocytosis. Abdominal MRI showed hepatosplenomegaly with hepatic iron overload. In this context of haemolysis (without anaemia) and iron overload, a diagnosis of haemochromatosis was presumed. NGS confirmed the presence of the variants p.(His63Asp) and p.(Cys282Tyr) in heterozygosity in the HFE gene. We report this case for the rarity of co-existing two haematological diseases counteracting each other.
PROBLEM TO BE SOLVED: To provide a method for using soluble CD24 for therapy of rheumatoid arthritis.SOLUTION: The present invention provides a method for treating rheumatoid arthritis by administering a CD24 protein to a mammal in need thereof. The CD24 protein may comprise the sequence of mature mouse CD24 or mature human CD24, or a variant thereof. The mature human CD24 may consist of the sequence of SEQ ID NO: 1 or 2. The mature mouse CD24 may consist of the sequence of SEQ ID NO: 3. The CD24 protein may also comprise the extracellular domain of mouse or human CD24, which may be fused to the N-terminal end of the mature CD24. The extracellular domain of CD24 may consist of the sequence of SEQ ID NO: 4. The CD24 protein may further comprise a portion of a mammalian immunoglobulin (Ig), which may be fused to the N-terminus or C-terminus of the mature CD24.SELECTED DRAWING: None
Aflatoxin B1 (AFB1) is one of the most harmful and toxic mycotoxins in foods and feeds, posing a serious health risk to both humans and animals, especially its hepatotoxicity. Nuclear factor-erythroid 2-related factor 2 (Nrf2), an important nuclear transcription factor, is generally recognized as a potential target for phytochemicals to ameliorate liver injury. The current study sought to elucidate the molecular processes by which licochalcone A (Lico A), a compound derived from Xinjiang licorice Glycyrrhiza inflate, protects against AFB1 toxicity. In vivo, male wild-type (WT) and Nrf2 knockout (Nrf2-/-) C57BL/6 mice were orally administered AFB1 at 1.5 mg/kg body weight (BW) with or without Lico A at 5 mg/kg. In vitro, AML12 cells were utilized to evaluate the protective effect and mechanism of Lico A against the AFB1-induced hepatotoxicity. Our findings demonstrated that AFB1 caused severe hepatotoxicity, while Lico A treatment successfully relieved the toxicity. Meanwhile, Lico A effectively improved liver injury, inflammatory mediators, oxidative insults, apoptosis, liver fibrosis, and pyroptosis, which contributed to the inhibition of toll receptor 4 (TLR4)-NF-κB/MAPK and NOD-like receptors protein 3 (NLRP3)/caspase-1/GSDMD signaling pathway activation. Furthermore, Lico A was able to enhance the Nrf2 antioxidant signaling pathway. Intriguingly, Lico A still had a protective effect on AFB1-caused liver injury in mice via the inhibition of inflammation and pyroptosis, while apoptosis and liver fibrosis were blocked in the absence of Nrf2. To sum up, the present study first elucidated that Lico A ameliorated AFB1-induced hepatotoxic effects and its main mechanism involved the inhibitory effects on oxidative stress, apoptosis, liver fibrosis, inflammation, and pyroptosis, which might be partially dependent on the regulation of Nrf2. The work may enrich the role and mechanism of Lico A's resistance to liver injury caused by various factors, and its application is promising.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention claims an agent comprising S-alkylisothiurnium as an active substance of the formula  , where Alk is the branched or nonbranched C 1 -C 4 -alkyl and x -  is anion of phosphorus- containing acid. A new agent is deprived of undesirable adverse effects typical for adrenomimetics exhibiting the same action. Invention can be used for production of preparations that effect on arterial pressure. EFFECT: expanded assortment of agents with hypertensive effect, valuable medicinal property. 3 cl, 14 dwg, 13 tbl, 3 ex
Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
The invention discloses a pharmaceutical composition with a synergistic hypoglycemic effect and application thereof. Relates to the technical field of medicines. The pharmaceutical composition consists of acarbose and icaritin. In vitro synergy experiments prove that the Combination Index (CI) of the combined application of acarbose and icaritin is less than 0.9, and the acarbose and icaritin have the synergistic effect of inhibiting the activity of alpha-glucosidase. Animal in vivo experiments prove that the composition has synergistic blood sugar reducing effect, and the effect of the composition is more remarkable than that of single acarbose or icaritin. The composition can effectively exert the synergistic effect of icaritin and acarbose, and has the advantages of improving the curative effect of acarbose, reducing the dosage of acarbose and reducing the side effect of acarbose.
Patients status post neoadjuvant therapy. Patients who received neoadjuvant will be enrolled into Cohort C to understand the correlation between TMEM MRI activity and TMEM doorway density following after neoadjuvant chemotherapy. Only patients with residual palpable mass on physical exam will be included (≥ 1cm). Patients will undergo TMEM-MRI after neoadjuvant therapy is completed. Patients will also have CTCs and ctDNA measured on the same day of TMEM-MRI (+/- 3 days). TMEM density, MenaCalc and MenaINV will be evaluated in breast surgical specimen (after pre-operative therapy). Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV after pre-operative therapy.
If alprazolam tablets are to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed, particularly with compounds which might potentiate the action of benzodiazepines (see DRUG INTERACTIONS).

As with other psychotropic medications, the usual precautions with respect to administration of the drug and size of the prescription are indicated for severely depressed patients or those in whom there is reason to expect concealed suicidal ideation or plans.

It is recommended that the dosage be limited to the smallest effective dose to preclude the development of ataxia or oversedation which may be a particular problem in elderly or debilitated patients. (See DOSAGE AND ADMINISTRATION.) The usual precautions in treating patients with impaired renal, hepatic or pulmonary function should be observed. There have been rare reports of death in patients with severe pulmonary disease shortly after the initiation of treatment with alprazolam. A decreased systemic alprazolam elimination rate (eg, increased plasma half-life) has been observed in both alcoholic liver disease patients and obese patients receiving alprazolam (see CLINICAL PHARMACOLOGY).

Episodes of hypomania and mania have been reported in association with the use of alprazolam in patients with depression.

Alprazolam has a weak uricosuric effect. Although other medications with weak uricosuric effect have been reported to cause acute renal failure, there have been no reported instances of acute renal failure attributable to therapy with alprazolam.
The participation of the study will be offered to each patient when they will come to the centre (by oncologist, radiotherapist, surgeon, ...). For the health staff, the information can be delivered through different channels (posting, mail, mail, intranet...). This will make the informed consent available to all staff. Participation will be voluntary: staff who have read the information note and wish to participate in the study will have to register on the "PAPESCO-01" screening schedule, during which they will sign their consent with the occupational physician (or anyone delegated by occupational medicine), then have their first sample and complete the various questionnaires.

The screening of the patients and of the health staff will be done by 2 or 3 techniques depending of the results. The first technic is a blood test done at M0 (inclusion), M3, M6, M9 and M12 and on demand in case of Covid-19 symptoms (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens (only at M0)). The second technic nasal swab test (RT-PCR) is done only in case of symptoms (whatever the result of the minute test is) for the hospitalized patients. The results of the tests realised in town will be get back through the questionnaires. The third technic is the questionnaires to the patients and the health staff.
Introduction: according to the World Health Organization (WHO), obesity has tripled in the world as a result of high caloric intake. People with disabilities are more likely to be overweight and obese. Objectives: this study aimed to estimate the association between disability status and consumption of sugar-sweetened beverages in the population aged 18 years and older in Colombia in 2017. Methods: we conducted a secondary analysis of data from Colombia's 2017 National Quality of Life Survey (ECV). The dependent variable was the consumption of sugar-sweetened beverages, and the independent variable was the disability status. Additionally, confounding variables were incorporated. An ordinal logistic regression was performed to estimate the magnitude of the association. The complex sample design of the 2017 LCS was considered in all results. Results: we included data from 18,957 persons aged 18 years and older; 7.9 % had a disability, and 64.4 % consumed sugar-sweetened beverages. People with moderate and severe disability were 18 % and 41 %, respectively, less likely to have a higher consumption of sugar-sweetened beverages compared to people without disability (OR: 0.82; 95 % CI: 0.72-0.95 and OR: 0.59; 95 % CI: 0.39-0.90). When stratified by age group, this association remained only in those older than 45. Conclusions: in Colombia, in 2017, people with disabilities older than 45 years consumed fewer sugar-sweetened beverages than people without disabilities.
Pneumonia complicating stroke is very difficult to manage and has a very poor prognosis, leading to a significantly higher risk of death. Oral opportunistic pathogens have been reported to be associated with the incidence of pneumonia among non-stroke immunocompromised subjects. Preliminary studies found that patients with stroke had higher carriage rates of oral opportunistic pathogens than healthy subjects. Therefore, investigators hypothesize that pneumonia complicating stroke is associated with oral opportunistic pathogens, and oral health promotion interventions may reduce the incidence of pneumonia complicating stroke via its effects on the species and relative abundance of oral opportunistic pathogens. In order to prove this, investigators need to (1) firstly conduct a randomized controlled trial to confirm whether oral health promotion is able to reduce the levels of plaque, and the incidence of pneumonia complicating stroke at clinical level; (2) secondly employ metagenomics analysis to compare oral rinse samples and respiratory samples, and to identify pneumonia-associated "oral opportunistic pathogens group"; (3) finally elucidate how oral health promotion influences the species and relative abundance of oral opportunistic pathogens. This proposed study will provide evidence for the integration of oral health promotion as part of interdisciplinary stroke rehabilitation.
The present invention discloses a drug for curing psoriasis and a preparation method thereof, which belongs to a Chinese drug preparation. The present invention is mainly used for curing psoriasis and the solving the problem of relapse. The components has the weight ratio of 8 to 18 shares of sulfur, 1 to 3 shares of spodium, 6 to 10 shares of sesame oil, 6 to 18 shares of rhizoma, 9 to 16 shares of alum and 8 to 19 shares of hair. The alum and the hair are ground into powder after being treated, and the powder is mixed with the powder of the sulfur, the spodium and the rhizoma, and then the powder are prepared into paste. The present invention medically overcomes the defects that the pathogenesis of psoriasis is unclear, the disease course is long, the relapse is easy, and the psoriasis is hard to cure. The present invention is mainly used for curing psoriasis.
The present invention relates to a medicine for treating toothache, which overcomes the defects that toothache is difficult to completely and rapid alleviate by the existing preparation, and inflammation and tumescence are difficult to eliminate in time so that the pain of patients can not be removed in time. Mirabilite, kudzu roots, ledebouriella seseloides and asarum herb are used as raw materials, the mirabilite, the kudzu roots, the ledebouriella seseloides and the asarum herb are mixed according to proportion after the raw materials are respectively ground and sieved, and the raw materials are uniformly blended to be made into powder. The present invention can be directly and externally applied to a toothache part to rapidly alleviate ache and eliminate tumescence. Clinical use indicates that the effective rate of the medicine for treating toothache of the present invention reaches 100%, and the cure rate reaches 98.34%. the present invention has the advantages of fast effects, ache alleviation in one minute, favourable effects, no contraindication and wide application range. The medicine for treating toothache is an ideal external application medicine for clinically treating toothache and oral diseases.
Patients undergo leukapheresis over 90 minutes. Patients then receive ST-alpha-DC1 IT on days 1, 8, and 50 in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV on days 8, 29, 50, and 71 in the absence of disease progression or unacceptable toxicity. Patients who are receiving clinical benefit from treatment at the end of day 85, may continue to receive pembrolizumab IV every 3 weeks beyond the 4 study doses. Patients also undergo tumor biopsies on days 1, 8, and 50 and CT scans at baseline and days 50 and 85.
One major problem with adenovirus gene therapy has been the T-cell mediated immune response elicited by inoculation of adenovirus, which leads to rapid clearance of the virus and loss of transgene expression. In the instant invention, the immune response to a virus is prevented by pre-treatment with adenovirus, adenoassociated virus or herpes virus infected antigen-presenting cell (APC) expressing Fas ligand with induced T-cell tolerance. Administration of AdCMVLacZ after tolerance resulted in prolonged expression of LacZ in tolerized animals compared to control treated animals. In control, but not tolerized animals, there was proliferation of CD3+ T-cell in the spleen in response to AdCMVLacZ treatment. Tolerance induction is also indicated by decreased production of interferon-η and IL-2 by peripheral T-cells isolated from treated animals after stimulation with the adenovirus infected APCs. T-cell tolerance is specific for the virus as the T-cell responses to an irrelative virus, mouse cytomegalovirus (MCMV) remained unimpaired. The instant invention utilizes virus specific T-cell tolerance, which is induced by APCs that co-express Fas ligand and virus antigens. The instant invention involves novel vectors and methods to induce tolerance to a viral vector gene therapy and prolong expression of a transgene in a viral host.
Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS MK-4830 800 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. MK-4830 will be administered by IV infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
This disclosure relates generally to method and system for determining myocardial ischemia severity based on hemodynamic parameters estimation. Many patients suffer from myocardial ischemia due to narrowing of coronary artery resulting poor oxygen supply in cardiac muscles. The method includes receiving Electrophysiology (EP) signal from a simulated heart surface model to generate a single lead ECG template. The method further estimates hemodynamic parameters using a hemodynamic module based on the single lead ECG template and then estimates cardiac pressure-volume loop variables. The myocardial ischemia severity of the heart surface model is determined which includes one of moderate ischemia, severe ischemia and silent ischemia. Here, the cardiac source module is coupled with the hemodynamic module to determine cardiac transmembrane potential (TMP) of the heart surface model through contractility function. This method serves as a guidance platform for patient care such as synthetic data generation for disease classification pertaining to coronary artery.
FIELD: organic chemistry of heterocyclic compounds, biochemistry, pharmacy. SUBSTANCE: invention describes method of synthesis of compound (1.3.0)   where   is a group taken among the formulas (1.3.2)  , (1.3.3)  , (1.3.4)   or (1.3.5)   involving the formation of reactive mixture consisting of carboxamide of the formula (2.0.0)   and the corresponding bicyclic N-heterocycle in aprotonic solvent in the presence of strong base in solid form taken among the group including sodium hydroxide and potassium hydroxide and, optionally, in the presence of catalytical amount of cesium carbonate, Cs 2 CO 3 , or catalyst of interphase transfer followed by heating the indicated reactive mixture under nitrogen atmosphere and yielding the end compound. Also, invention describes method of synthesis of one of particular compound and method of synthesis of compound mesilate salt. Synthesized compounds can be useful for treatment of patients with inflammatory diseases and allergy. EFFECT: improved method of synthesis of known and new inhibitors of 5-lipoxygenase, valuable medicinal properties of compounds. 8 cl, 3 tbl, 18 ex
All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
Participants in this group will receive a group-based, supervised exercise session twice a week for 10 weeks along with a structured home exercise program. These sessions will be delivered via Boston University HIPAA-compliant Zoom videoconferencing software.
BACKGROUND: Interstitial Pneumonitis (IP) is one of the pulmonary complications associated with mammalian Target of Rapamycin-Inhibitors (mTOR-Is). Sirolimus and everolimus belong to mTOR-Is. According to studies, IP is caused by both.
CASE PRESENTATION: This is a case report in a kidney transplant recipient. We want to present a case of IP after 50 months of sirolimus consumption. Sirolimus was discontinued, and cyclosporine was started. Thirty-seven months later, everolimus was prescribed as an alternative to cyclosporine due to the recurrence of skin Squamous Cell Carcinoma (SCC). Fortunately, no respiratory manifestations were seen after more than 8 years of everolimus consumption.
CONCLUSIONS: In conclusion, in cases with sirolimus-induced IP, discontinuation of sirolimus and replacement with everolimus are recommended after resolving clinical symptoms and pulmonary lesions.
FIELD: medicine.SUBSTANCE: invention refers to medicine, nutriology, dietology, immunology, endocrinology. Method includes correction of metabolic disorders in persons of working age with increased body weight index (BWI). Against the backdrop of a low-calorie diet, preparations of metabolic action – Fucus Jelly Native Gastro, Hepamin and Stimbiphid – are taken. Fucus Jelly Native Gastro is taken in amount of 40 g 2 times day 20–30 minutes before meals, mixing the preparation with water or a fruit beverage. If BWI is increased by 1-2 units from upper limit of norm – within 1.5 months, increased BWI by 3-4 units from upper limit of norm – to its reduction by 2 units, increased BWI by more than 4 units from upper limit of norm – to its reduction by 3 units. Hepamin is taken with meals 3 times a day: 2 tablets with high BWI from 1 to 3 units from upper limit of norm to BWI reduction by 1 unit; 3 tablets with high BWI for more than 3 units from upper limit of norm to reduction of BWI by 2 units. Stimbiphide – on the first day of 1 tablet 2 times a day – in the morning and in the evening, in second – 2 tablets 2 times a day, in third – 2 tablets 3 times a day, then take 3 tablets 3 times a day until normalizing BWI.EFFECT: method enables long-term preservation of positive biochemical effects, normal intestinal microbiota, bringing the required micro- and macronutrients into the body balance, bringing the blood glucose, lipidogram, hepatic enzymes, number of fat deposits, immunogram values by reducing the amount of adipose tissue and extracellular fluid, increasing active cell and musculoskeletal body weight, operability and intensity of metabolism.1 cl, 4 tbl
A coating composition comprising a chromic component comprising liquid crystal (LC), and a curable oligomer and/or monomer, and a curing initiator. The LC may be a cholesteric LC and/or a phenyl benzoate ester and may be present from 35-75 wt%. The composition may include a colourant, which may be selected from a static liquid crystal, dye or pigment, which may be a powder or a non-aqueous solution. The LC may be unsealed. The oligomer and/or monomer may be dissolved or dispersed in a non-aqueous solvent, or it may be polar and immiscible with the liquid crystal. The oligomer may comprise urethane, e.g. aliphatic urethane methacrylate. The monomer may be one or more of hydroxyl-substituted alkyl acrylate, alkyl methacrylate, isobornyl methacrylate. It may include a UV absorber, which may be insoluble in water. The composition may be adapted to coat nails, and it may be a gel. Also provided is a cured coating composition derived for the coating composition, to provide a continuous phase coating, and a method to form it. Also provided is the use of a liquid crystal coating comprising a continuous polymer matrix derived from a curable oligomer and/or monomer to provide a colour-change effect on a substrate.